Henry Schein, Inc. (NASDAQ:HSIC) Shares Acquired by Everett Harris & Co. CA

Everett Harris & Co. CA raised its position in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 29.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 104,677 shares of the company's stock after buying an additional 23,622 shares during the quarter. Everett Harris & Co. CA owned about 0.08% of Henry Schein worth $7,925,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. lifted its holdings in Henry Schein by 2.4% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company's stock valued at $459,000 after purchasing an additional 122 shares in the last quarter. HighTower Advisors LLC raised its holdings in Henry Schein by 18.9% in the 1st quarter. HighTower Advisors LLC now owns 14,030 shares of the company's stock valued at $1,220,000 after buying an additional 2,226 shares during the period. MetLife Investment Management LLC raised its holdings in Henry Schein by 23.2% in the 1st quarter. MetLife Investment Management LLC now owns 37,733 shares of the company's stock valued at $3,290,000 after buying an additional 7,095 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Henry Schein by 6.6% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,555 shares of the company's stock valued at $1,618,000 after buying an additional 1,149 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Henry Schein by 4.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,300,357 shares of the company's stock valued at $113,386,000 after buying an additional 51,106 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on HSIC. Barrington Research lifted their target price on Henry Schein from $82.00 to $90.00 and gave the company an "outperform" rating in a research report on Wednesday, February 28th. Jefferies Financial Group lifted their target price on Henry Schein from $74.00 to $81.00 and gave the company a "hold" rating in a research report on Wednesday, March 6th. SVB Leerink initiated coverage on Henry Schein in a research report on Monday, February 26th. They set a "market perform" rating and a $78.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on Henry Schein from $82.00 to $88.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 6th. Finally, Evercore ISI boosted their price objective on Henry Schein from $79.00 to $83.00 and gave the stock an "in-line" rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $81.09.

Henry Schein Price Performance

HSIC stock traded up $0.37 on Friday, reaching $75.52. 1,014,939 shares of the company's stock were exchanged, compared to its average volume of 1,190,878. The stock has a fifty day moving average of $75.23 and a 200-day moving average of $72.67. Henry Schein, Inc. has a twelve month low of $60.01 and a twelve month high of $85.75. The firm has a market cap of $9.71 billion, a PE ratio of 23.97, a P/E/G ratio of 1.86 and a beta of 0.87. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.04). The firm had revenue of $3.02 billion during the quarter, compared to analyst estimates of $3 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The firm's revenue for the quarter was down 10.5% on a year-over-year basis. During the same period last year, the company posted $1.21 EPS. As a group, equities analysts predict that Henry Schein, Inc. will post 5.07 EPS for the current fiscal year.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the company's stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the sale, the chief executive officer now owns 73,108 shares of the company's stock, valued at $5,430,462.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares in the company, valued at $5,430,462.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the firm's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.